AJTMH Tropical Medicine and Hygiene News
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am. J. Trop. Med. Hyg., 55(2), 1996, pp. 219-222
Copyright © 1996 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wittner, M.
Right arrow Articles by Weiss, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wittner, M.
Right arrow Articles by Weiss, L. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ATOVAQUONE

Atovaquone in the Treatment of Babesia microti Infections in Hamsters

Murray Wittner, Jeffrey Lederman, Herbert B. Tanowitz, Gary S. Rosenbaum AND Louis M. Weiss
Departments of Pathology (Division of Parasitology) and Medicine (Infectious Diseases Division) Albert Einstein College of Medicine, Bronx, New York; Southampton Hospital, Southampton, New York

The traditional therapy for the treatment of human Babesia microti infections has been the combination of clindamycin and quinine. However, in recent years, it has become apparent that some patients have not responded to this regimen. We became involved in the treatment of several cases of babesiosis in which atovaquone was used to treat this infection. Therefore, using the hamster model, we determined the efficacy of atovaquone alone as well as atovaquone plus azithromycin for the treatment of experimental babesiosis. Atovaquone (100 mg/kg/day) and atovaquone (100 mg/kg/day) with azithromycin (150 mg/kg/day) were effective agents for the treatment of experimental babesiosis in hamsters. When atovaquone was used as monotherapy recrudescences occurred. Organisms obtained from recrudescent animals, when inoculated into uninfected animals, proved to be unresponsive to atovaquone therapy, suggesting the emergence of drug resistance. Resistant organisms did not emerge in hamsters treated with the combination of atovaquone and azithromycin. Atovaquone should be considered in the therapeutic regimen of patients with babesiosis who have either failed standard therapy or have become intolerant to such therapy.




This article has been cited by other articles:


Home page
Am J Trop Med HygHome page
D.-M. KIM, K. J. WON, C. Y. PARK, K. D. YU, H. S. KIM, T. Y. YANG, J. H. LEE, H. K. KIM, H.-J. SONG, S.-H. LEE, et al.
DISTRIBUTION OF ESCHARS ON THE BODY OF SCRUB TYPHUS PATIENTS: A PROSPECTIVE STUDY
Am J Trop Med Hyg, May 1, 2007; 76(5): 806 - 809.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
J. Dobroszycki, B. L. Herwaldt, F. Boctor, J. R. Miller, J. Linden, M. L. Eberhard, J. J. Yoon, N. M. Ali, H. B. Tanowitz, F. Graham, et al.
A Cluster of Transfusion-Associated Babesiosis Cases Traced to a Single Asymptomatic Donor
JAMA, March 10, 1999; 281(10): 927 - 930.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Society of Tropical Medicine and Hygiene.